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Cardiomyopathy (CMP) is the heart muscle disease causing cardiac myocyte injury and
myocardial dysfunction, which impair structural and/or functional ventricular filling or
ejection of blood in the absence of structural or vascular heart disease. Most CMPs are complex
and heterogeneous familial diseases, and the inheritance is autosomal dominant in majority
of cases. The classification of these cardiac diseases has been based on morphofunctional
phenotypes, but it has been changed according to molecular genetics in recent years. As we
know, the traditional classification proposed by the World Health Organization (WHO) is easy
to differentiate between various CMPs in a couple structural and functional phenotypes (Table
1), which helps us to define common treatment strategies [1]. New classification-orientated
genomic and molecular science helps us to understand the complexity and heterogeneity of
these diseases (Table 2), which may occur primary or secondary [2]. The American Heart
Association (AHA) Scientific Statement proposes the definition: “Cardiomyopathies are a
heterogeneous group of diseases of the myocardium associated with mechanical and/or
electrical dysfunction that usually (but not invariably) exhibit inappropriate ventricular
hypertrophy or dilatation and are due to a variety of causes that frequently are genetic.
Cardiomyopathies either are confined to the heart (primary) or are part of generalized systemic
disorders (secondary), often leading to cardiovascular death or progressive heart failure-
related disability.” The last classification system (MOGES) proposed by the World Heart
Federation (WHF) includes all characteristics: morphofunctional phenotype (M), organ(s)
involvement (O), genetic inheritance (G), etiology (E), and functional status (S) (Table 3) [3].
From the clinical perspective, the most important objective is diagnosis of the mechanism of
the heart failure and delivery of the appropriate effective treatment. Heart failure incidence
increases with age and rises from 20% in the seventh decade to more than 80% in octogenari-
ans [4]. Advancing age or cardiac aging is another risk factor for heart failure, and it is a
heterogeneous process characterized by genomic DNA damage, telomere shortening, and
epigenetic modifications, which can affect protein homeostasis, mitochondrial function, and
regenerative potential of stem cells adversely [5]. The hemodynamic changes are dependent
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on the nature of cardiomyopathies, which cause myocardial dysfunction due to mechanical or
arrhythmogenic pathophysiologic mechanisms.
1. Dilated
2. Hypertrophic
3. Restrictive
4. Arrhythmogenic
5. Unclassified (mitochondrial diseases, fibroelastosis)
6. Specific
a. Ischemic
b. Valvular
c. Hypertensive
d. Inflammatory
e. Metabolic
f. General systemic disease
g. Muscular dystrophies
h. Neuromuscular disorders
i. Sensitivity and toxic reactions
j. Peripartum
Table 1. World Health Organization (WHO) classification for cardiomyopathies.
A. Primary (predominantly involving the heart)
a. Genetic
1) Hypertrophic cardiohyopathy
2) Arrhythmogenic right ventricular dysplasia
3) Glycogen storage (PRKAG2, Danon)
4) Conduction defects
5) Mitochondrial myopathies
6) Ion channel disorders (LQTS, SQTS, CVPT, Brugada, Asian SUNDS)
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b. Acquired
1) Inflammatory (myocarditis)
2) Stress-provoked (Tako-Tsubo)
3) Peri- or postpartum
4) Tachycardia-induced
5) Infants of insulin-dependent diabetic mothers
c. Mixt
1) Dilated cardiomyopathy
2) Restrictive (non-hypertrophied and non-dilated)
2. Secondary
a. Infiltrative (amyloidosis; Gaucher disease; Hurler’s disease; Hunter’s disease)
b. Storage (hemochromatosis; Fabry’s disease; Glycogen storage disease = type II Pompe; Niemann-Pick disease)
c. Toxicity (drugs, heavy metals, chemical agents)
d. Endomyocardial (endomyocardial fibrosis; hypereosinophilic syndrome = Löeffler’s endocarditis)
e. Inflammatory = granulomatous (Sarcoidosis)
f. Endocrine (diabetes mellitus; hyperthyroidism; hypothyroidism; hyperparathyroidism; pheochromocytoma;
acromegaly)
g. Cardiofacial (Noonan syndrome; Lentiginosis)
h. Neuromuscular/neurological (Friedreich’s ataxia; Duchenne-Becker muscular dystrophy; Emery-Dreifuss
muscular dystrophy; myotonic dystrophy; neurofibromatosis; Tuberous sclerosis)
i. Nutritional deficiencies (Beriberi, pallagra, scurvy, selenium, carnitine, kwashiorkor)
j. Autoimmune/collagen (systemic lupus erythematosis; dermatomyositis; Rheumatoid arthritis; scleroderma;
polyarteritis nodosa)
k. Electrolyte imbalance
l. Consequence of cancer therapy (anthracyclines: doxorubicin (adriamycin), daunorubicin; cyclophosphamide;
radiation)
Table 2. American Heart Association (AHA) Classification for Cardiomyopathies.
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Table 3. World Heart Federation (WHF) MOGE(S) classification for cardiomyopathies.
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Cardiac contraction is a specific motion of myocardium that results in an adequate ejection
(>60%) with lower dynamic change and energy consumption (15% fiber shortening) [6].
Subendocardially located cardiomyocytes create right-handed helix (smaller-radius) and
subepicardially located cardiomyocytes left-handed helix (larger-radius), and this helixodical
structure of the myocardium generates a torsional motion pattern caused by rotation in a
clockwise direction at basal level and counter clockwise rotation at the apical level. In hyper-
trophic CMP, basal rotation increases and if the septum has sigmoid curvature apical rotation
is more certain, and both mechanisms increase outflow tract obstruction level, decrease
untwisting velocity, and cause subendocardial ischemia. In dilated CMP, the abnormal shape
of the left ventricle changes fiber orientation and increasing dilatation is associated with more
decreased twist.
The diagnosis of CMPs is assessed echocardiographically, but cardiovascular magnetic
resonance (MR) is also powerful tool in diagnosis. Both are complementary imaging modali-
ties. Echocardiography is superior in assessment of diastolic function and dynamic outflow
tract obstruction. Cardiac MR has several advantages such as three-dimensional visualization,
demonstration of relationships between the heart and thoracic structures, quantification of
cardiac volumes and function, excellent resolution, tissue characterization (scar or infiltration),
safely repetition [7].
1. Irreversible cardiomyhopaties
Dilated CMP is the most common (>60%) final pathway during clinical nature of CMPs, which
has more than 50% idiopathic etiology. Furthermore, some infiltrative CMP diseases may
progress, as a consequence of remodeling, from one state (non-dilated) to another (dilated)
during their natural clinical course. Mechanical impairment of filling or ejecting of ventricles
causes significant cardiac decompensation with a clinic presentation from asymptomatic left
ventricular dysfunction to severe heart failure symptoms. Annual mortality ratio changes
between 10 and 50%, whereas between 1/4 and 1/3 of patients with new-onset dilated CMP
presents cardiac recovery. Reverse remodeling may develop spontaneously or occur after
medical or device treatment. Most patients have normal coronary circulation, and a definition
for ischemic CMP needs a >70% stenosis in a major epicardial coronary artery. The main
pathophysiologic mechanism is progressive systolic dysfunction dependent on four-chamber
dilatation of the heart with normal left ventricular wall thickness. The annular enlargement
causes significant valvular insufficiency, which makes the clinical status worse. Pulmonary
hypertension with increased pulmonary vascular resistance develops gradually and diagnosis
can result from cardiac catheterization. The diagnosis and management of patients with CMP
are evaluated with noninvasive (echocardiography, MR imaging, multidetector computed
tomography) or invasive cardiac tests (cardiac catheterization, endomyocardial biopsy). Large-
scale treatment options give clinicians a wide range of follow-up of their patients. Asympto-
matic patients can be followed medically, but mild-moderate symptomatic patients must be
treated pharmacologically (diuretics, neurohormonal antagonists, anti-pulmonary hyperten-
sives). Severe symptomatic conditions require invasive treatment options in a sequence: anti-
Introductory Chapter: Last Crossroad
http://dx.doi.org/10.5772/65368
7
arrhythmogenic devices, anti-regurgitant devices, anti-failure mechanic devices, and heart
transplantation. Assessment of exercise capacity guides this treatment sequence, and 6-min
walk test is the simplest valuable tool for switching to invasive treatments. The best test to
gradate exercise capacity and to determine the cardiac-cause is the cardiopulmonary exercise
testing, which is the most important test to determine whether to put patients on to waiting
list.
Hypertrophic CMP is the most common cardiomyopathy with genetic transmission and
characterized by a thickened, hypertrophied left ventricle without dilatation. Hypertrophic
CMP is caused by a variety of mutations encoding contractile proteins of the cardiac sarcomere.
Hypertrophy is usually diffuse and involves both septum and left ventricular free wall (≥15
mm; +family history 13–14 mm; in children ≥ +2 standard deviation). Diastolic dysfunction
develops due to the presence of a small left ventricular cavity; contrarily, systolic function can
be preserved at the beginning of the pathology. Longstanding left ventricular outflow tract
obstruction due to ventricular thickness with or without systolic anterior motion of mitral valve
is the main predictor of heart failure or sudden death. Myocardial ischemia occurs due to
microvascular dysfunction, which results in left ventricular scarring and remodeling. Reduced
ventricular compliance causes diastolic dysfunction, which is diagnosed by exertional
dyspnea. The greatest risk for adverse outcome is arrhythmogenic complication without heart
failure symptoms. Atrial fibrillation is the most common (20%) rhythm disorder and cannot
be tolerated well and results in embolic stroke or progressive heart failure. The lethal arrhyth-
mia is ventricular fibrillation and has several signs: family history, unexplained syncope,
hypotensive blood pressure response to exercise, abnormal ventricular tachycardia, massive
left ventricular hypertrophy. The first stage treatment is the implantation of a cardioverter-
defibrillator. Dual chamber pacing has limited effect. Septal myectomy or alcohol septal
ablation is an alternative invasive treatment option, but heart transplantation is the final and
only option for curative therapy.
Restrictive CMP appears increasing in stiffness of the ventricular walls and consequently
developing diastolic failure. At the beginning, the systolic function is normal, but it decreases
during the progress of the disease. The most common specific etiology is amyloidosis. The
pathologic changes of impairment of diastolic filling are myocardial fibrosis, infiltration or
scarring of the endomyocardial surface. The first symptom is exercise intolerance, but with
advancing disease, volume balance shifts to the generalized edema due to diastolic dysfunction
and to the filling reduction in ventricles due to diuresis. In the late period of the restrictive
CMP, ventricular dilatation can be added to the pathology and prognosis deteriorates rapidly.
Treatment options are limited: anti-arrhythmogenic devices, biventricular pacing, and heart
transplantation. Left ventricular assist devices (LVAD) cannot be used in this group of diseases.
Arrhythmogenic right ventricular dysplasia is a rare, inherited pathology that is characterized
by ventricular arrhythmias, sudden cardiac death, and right ventricular dysfunction due to
myocyte loss with fatty or fibro-fatty tissue replacement of the right ventricular myocardium
(and less commonly left). The pathophysiologic basis of this disease can be dependent on
defective desmosomal proteins (impaired mechanical coupling between individual cells) or
intracellular signaling pathways [8]. Several genes and gene loci are associated with this
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disease, but cardiac magnetic resonance and signal-averaged electrocardiography are more
definitive diagnostic tests than endomyocardial biopsy. Genetic testing is essential for family
screening, because more than 60% of patients have a pathogenic mutation. The natural
progress of the pathology has four steps: asymptomatic period, arrhythmogenic period,
development of the right heart failure, and finally biventricular failure. The prior clinic course
is syncope or sudden death (20%) before development of heart failure, which is the late
manifestation of the disease. Diagnosis must be evaluated on major and/or minor criteria,
where several signs on the electrocardiography are essential for diagnosis: T wave inversion
in the right precordial leads (v1–v3), right bundle branch block, Epsilon wave, and terminal
activation delay. Because prevention of sudden cardiac death caused by ventricular arrhyth-
mias is the primary goal of management, a cardioverter-defibrillator implantation is the first
stage of the therapy. Beta-blocker therapy with exercise restriction should be included in the
medical treatment, because exercise is the only triggered predictor for ventricular arrhythmias
and sudden death. But, the curative treatment for significant heart failure is the cardiac
transplantation.
2. Specific reversible cardiomyopathies
Secondary CMPs affects the myocardium in a multi-organ approach. There are several etiologic
diseases that impair the physiologic functions of the heart and cause structural changes, which
can result in chronic heart failure and/or arrhythmias [9]. Most of them are reversible, if the
appropriate management is implemented.
Ischemic CMP is included in dilated CMP group with the highest frequency (2/3–3/4 of all
cases). Hibernating, stunning or severe ischemic myocardium make the clinical status worse
temporarily, but diffuse fibrosis or necrotic and scarred myocardium results in irreversible
myocardial dysfunction. In the presence of viable tissue, coronary revascularization with or
without surgical correction of mechanical complications may remove this adverse remodeling.
Transmural myocardial infarction, incomplete coronary revascularization, coronary bypass
graft failure or inadequate myocardial protection during open-heart surgery can trigger
ischemic CMP. If ischemia cannot be resolved, this pathology causes irreversible remodeling
and left ventricular dilatation, therefore medical treatment is poor. Mechanical complications
of coronary artery disease such as mitral regurgitation and left ventricular aneurysm can
complicate the clinic course and precipitate heart failure, but surgical treatment modalities of
heart failure can only extend patient-life. Left ventricular assist device or heart transplantation
must be the preferred treatment in patients with end-stage heart failure. In limited cases, left
ventricular reconstruction associated coronary revascularization can terminate irreversible
remodeling phase and improve left ventricular function.
Myocarditis is defined as inflammation of the myocardium, and it has an acute or chronic
process. The pathology is characterized by inflammatory cells, interstitial edema, focal
myocyte necrosis, and fibrosis, whereas autoimmune reaction can cause myocardial damage.
Etiologic factors are different: infectious agents (viruses), toxins, drugs, cytotoxic chemother-
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apy, and hypersensitivity reactions. Viral cause (coxsackie, cytomegalovirus, HIV, etc.) is the
most common reason for myocarditis, and three pathophysiological phases show pathologic
course: viral, immunologic response, and cardiac remodeling phases. The most important
phase is the immunologic response with a dual role. It is activated to eliminate as many virus-
infected cells as possible to control the infection. Second role is the control of this response to
prevent excessive tissue damage and organ dysfunction against monoclonal antibodies, which
attack directly to receptors on viruses and also receptors on cardiomyocytes. This causes in
subacute and chronic inflammation, which results in myocyte necrosis, fibrosis, and remod-
eling. Ventricular remodeling includes chamber dilatation, regional hypertrophy, and regional
wall motion abnormalities. Patients with mild cardiac involvement will generally recover
without long-term sequel, whereas chronic form has a lower recovery rate (30%) and the
majority develops dilated CMP. The first-line therapy is supportive care; a hemodynamic
support can be necessary in a small group of patients. Patients with end-stage heart failure
must be treated with mechanical support using LVAD or heart transplantation.
Sepsis-induced CMP occurs very common (60%) during sepsis or septic shock with high
incidence of death. The myocardium is functionally and structurally injured by inflammatory
cytokines and mitochondrial dysfunction [10]. It has a classical triad: affecting both ventricles
and causing global ventricular dysfunction (decreasing biventricular ejection fraction), left
ventricular dilatation (diastolic dysfunction with elevated left ventricular end-diastolic
volume), and recovery in 7–10 days. Chemical mediators (endotoxins, cytokines, histones, and
nitric oxide) decrease myofibril response to calcium, downregulate β-adrenergic receptors and
induce mitochondrial dysfunction. The therapy should include antibiotics, vasopressor
support, and perhaps, plasmapheresis. Inotropic catecholamines support, such as dobutamine
and dopamine, is not suggested due to causing of hyperkinesis; on the contrary, β-blockade
may be effective by lowering adrenergic stimulation. Levosimendan and/or intra-aortic
balloon pumping can improve myocardial function and cardiac output.
Peripartum CMP is a rare phenotype of dilated CMP, and congestive heart failure can develop
in the third trimester of pregnancy or the first 6 months postpartum. The cause is unknown,
but this cardiomyopathy develops generally in obese, multiparous women >30 years of age
with preeclampsia. The pathologic etiology is increased fetomaternal transfer of cells (fetal
microchimerism), which may trigger an exaggerated autoimmune response in the postpartum
period [11]. Peripartum CMP can recover completely or almost completely within 6 months
in a half of patients, if not, progressive cardiac failure is the prognosis requiring LVAD support
or heart transplantation.
Sympathoexcitation-induced CMP is also known as stress or Takotsubo CMP, or apical
ballooning syndrome. It is most present in older women like an acute coronary syndrome
without any angiographic findings. Increased catecholamines lead to elevation of systemic
vascular resistance and systolic blood pressure, and cardiac output. During hypercontraction
of the left ventricle, basal segments of the left ventricle contract more strongly than mid and
apical segments, and that asynchronism increases stress in the left ventricular apex and
produces a balloon-like appearance of the distal left ventricle during systole (regional dys-
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function). Restriction of exercise and the use of β-adrenergic blockers return the left ventricular
function to normal within a few weeks.
Metabolic CMP can develop secondary to several endocrine diseases, familial storage
pathologies, or nutritional deficiencies. Typical phenotype is thyroid dysfunction, where
dysthyriodism (hyper- or hypothyroidism) causes a low cardiac output CMP. Thyroid
hormones act as receptors and ion channels in the myocardium to improve myocardial
function, and they also have a peripheral vasodilatory effect to reduce peripheral vascular
resistance. Both pathologies cause heart failure by upregulation or downregulation of the
previously mentioned myocardial structures. ß-adrenoreceptor blockers normalize the left
ventricular mass index and systolic function after treatment, and also prevent atrial arrhyth-
mias.
Cirrhotic CMP is a chronic cardiac dysfunction without any cardiac disease and develops
secondary to end-stage liver failure caused by several factors, especially by toxic effect of
alcohol. The pathophysiologic changes include attenuated systolic contractile response to any
strain, diastolic dysfunction, electrophysiological abnormalities, and chronotropic incompe-
tence. The typical hemodynamic signs of alcoholic cirrhosis are hyperdynamic circulation with
high cardiac output, decreased peripheral resistance and arterial pressure. Depression or
desensitization of β-adrenergic receptors impairs chronotropic and inotropic responses of the
heart and can be the early sign of cirrhotic CMP [12]. The second mechanism is downregulation
of intracellular calcium kinetics. The third mechanism is rising of circulatory vasodilatations
such as nitric oxide (peripheral), carbon monoxide (hepatic), and endocannabinoids (splanch-
nic), which can have adverse effect on the heart. Because CMP worsens with the progression
of the underlying liver failure, liver transplantation with withdrawn of alcohol is the first-line
therapy to reverse cardiac failure.
Obesity (lipotoxic) CMP has hyperdynamic circulation because of increased adipose tissue
metabolism, which may cause left ventricular hypertrophy and dilatation. Obesity is one of
the main causes of insulin resistance and hyperglycemia, and glucotoxicity increases patho-
physiologic changes. The other reasons can be an imbalance in the adiponectin-leptin ratio,
cardiac lipotoxicity or steatosis, and/or non-oxidative pathway induced by excess fatty acids.
All these changes cause defective intracellular signaling, chronic inflammation, intracellular
dysfunction, and apoptosis [13].
Diabetes mellitus-related CMP occurs due to myocardial microangiopathy or disturbed
myocardial metabolism in the absence of coronary artery atherosclerosis. It has two different
phenotypes: dilated left ventricular cavity with reduced ejection fraction or restrictive left
ventricular cavity with reserved ejection fraction [14]. In restrictive phenotype, the left ventricle
is normal sized but stiff with high resting tension due to hypertrophied cardiomyocytes with
normal sarcomeres and limited collagen deposition in-between cardiomyocytes. In dilated
phenotype, the left ventricle is enlarged due to damaged cardiomyocytes with loss of sarco-
meres and severe collagen deposition with fibrosis. Several pathophysiologic mechanisms
affect myocardial remodeling and dysfunction: hyperglycaemia, lipotoxicity, insulin resist-
ance, microvascular advanced glycation end-products deposition, microvascular rarefaction,
and autoimmunity (especially for dilated phenotype).
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